- Home
- LILAK vs SNDX Comparison
LILAK vs SNDX Comparison
Compare LILAK & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LILAK
- SNDX
- Stock Information
- Founded
- LILAK 2017
- SNDX 2005
- Country
- LILAK Bermuda
- SNDX United States
- Employees
- LILAK N/A
- SNDX N/A
- Industry
- LILAK Cable & Other Pay Television Services
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- LILAK Telecommunications
- SNDX Health Care
- Exchange
- LILAK Nasdaq
- SNDX Nasdaq
- Market Cap
- LILAK 1.3B
- SNDX 1.1B
- IPO Year
- LILAK N/A
- SNDX 2016
- Fundamental
- Price
- LILAK $6.87
- SNDX $13.67
- Analyst Decision
- LILAK Buy
- SNDX Strong Buy
- Analyst Count
- LILAK 3
- SNDX 10
- Target Price
- LILAK $10.27
- SNDX $36.20
- AVG Volume (30 Days)
- LILAK 862.0K
- SNDX 2.6M
- Earning Date
- LILAK 02-20-2025
- SNDX 02-25-2025
- Dividend Yield
- LILAK N/A
- SNDX N/A
- EPS Growth
- LILAK N/A
- SNDX N/A
- EPS
- LILAK N/A
- SNDX N/A
- Revenue
- LILAK $4,470,200,000.00
- SNDX $16,000,000.00
- Revenue This Year
- LILAK $1.17
- SNDX N/A
- Revenue Next Year
- LILAK $3.18
- SNDX N/A
- P/E Ratio
- LILAK N/A
- SNDX N/A
- Revenue Growth
- LILAK N/A
- SNDX N/A
- 52 Week Low
- LILAK $5.95
- SNDX $12.06
- 52 Week High
- LILAK $10.93
- SNDX $25.34
- Technical
- Relative Strength Index (RSI)
- LILAK 56.98
- SNDX 48.26
- Support Level
- LILAK $6.14
- SNDX $12.40
- Resistance Level
- LILAK $6.89
- SNDX $13.16
- Average True Range (ATR)
- LILAK 0.21
- SNDX 0.66
- MACD
- LILAK 0.09
- SNDX 0.14
- Stochastic Oscillator
- LILAK 84.97
- SNDX 62.16
About LILAK Liberty Latin America Ltd. Class C
Liberty Latin America Ltd is a telecommunications company. It is a provider of video, broadband internet, fixed-line telephony, and mobile services to residential and business customers. The company's reportable segments include C&W Caribbean, Liberty Networks, C&W Panama, VTR, Liberty Puerto Rico, and Liberty Costa Rica. The company generates the majority of its revenue from C&W Caribbean, and Liberty Puerto Rico segments.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.